IMNN (Imunon, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IMNN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | — |
| 2026-09-01 | Douglas Vincent Faller | Chief Medical Officer | A | — | — |
| 2026-09-01 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-09-01 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-08-17 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-08-17 | Douglas Vincent Faller | Chief Medical Officer | A | — | — |
| 2026-08-17 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | — |
| 2026-08-17 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-08-04 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | — |
| 2026-08-04 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-08-04 | Donald P Braun | Director | A | — | — |
| 2026-08-04 | Douglas Vincent Faller | Chief Medical Officer | A | — | — |
| 2026-08-04 | James E Dentzer | Director | A | — | — |
| 2026-08-04 | Christine A Pellizzari | Director | A | — | — |
| 2026-08-04 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-08-04 | Frederick J. Fritz | Director | A | — | — |
| 2026-07-21 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-07-21 | Douglas Vincent Faller | Chief Medical Officer | A | — | — |
| 2026-07-21 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | — |
| 2026-07-21 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-07-07 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | — |
| 2026-07-07 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-07-07 | Douglas Vincent Faller | Chief Medical Officer | A | — | — |
| 2026-07-07 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-06-29 | Susan Eylward | General Counsel and Corp Sec | MIXED | — | — |
| 2026-06-29 | Douglas Vincent Faller | Chief Medical Officer | A | — | — |
| 2026-06-29 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-06-29 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-06-23 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-06-23 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-06-09 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-06-09 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-05-27 | Donald P Braun | Director | A | — | — |
| 2026-05-27 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-05-27 | Frederick J. Fritz | Director | A | — | — |
| 2026-05-27 | James E Dentzer | Director | A | — | — |
| 2026-05-27 | Christine A Pellizzari | Director | A | — | — |
| 2026-05-27 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-01-06 | Stacy Lindborg | President and CEO | A | — | — |
| 2026-01-06 | Frederick J. Fritz | Director | A | — | — |
| 2026-01-06 | James E Dentzer | Director | A | — | — |
| 2026-01-06 | Michael H Tardugno | Executive Chairman of Board | A | — | — |
| 2026-01-06 | Christine A Pellizzari | Director | A | — | — |
| 2026-01-06 | Donald P Braun | Director | A | — | — |
| 2026-01-06 | Susan Eylward | General Counsel and Corp Sec | A | — | — |
| 2026-01-06 | Douglas Vincent Faller | Chief Medical Officer | A | — | — |
| 2026-01-06 | Khursheed Anwer | Chief Scientific Officer | A | — | — |
| 2026-01-06 | Kimberly Bragg | CFO | A | — | — |
| 2025-09-09 | Stacy Lindborg | President and CEO | M | — | — |
| 2025-08-06 | Kimberly Bragg | CFO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 100,854 | — |
| — | Executive Chairman of Board | 94,497 | — |
| — | Chief Medical Officer | 37,077 | — |
| — | Director | 21,897 | — |
| — | Director | 21,031 | — |
| — | Director | 15,499 | — |
| — | Director | 15,076 | — |
| — | General Counsel and Corp Sec | 2,896 | — |
| — | Chief Medical Officer | 1,533 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMNN quote page; the site-wide leaderboard is on the insider transactions hub.